THERAPY DOSSIER · th-6aa57adf82f8

L-alanyl-L-glutamine

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01831310 ↗PHASE4completed

Glutamine Dipeptide and/or Omega-3-Supplemented Parenteral Nutrition on Neutrophil Function

Malnutrition · Colorectal Cancer

Enrolment: 36 · Results not recorded

NCT01955772 ↗PHASE3unknown

Enteral (alanyl-glutamine, Dipeptiven) vs Parenteral Nutrition After Allogeneic HSCT

Myeloablative Allo-SCT

Enrolment: 240 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25470514 ↗2014Reported benefit

Prophylactic inhalation of L-alanyl-L-glutamine enhances heat shock protein 72 and attenuates endotoxin-induced lung injury in rats.

RatEndotoxin/LPSSprague-DawleyMaleInhalationProphylactic, 12 hours before lipopolysaccharide inhalation

Model: Acute lung injury induced by lipopolysaccharide inhalation

Glutamine inhalation increased lung HSP72 and, when given 12 hours before lipopolysaccharide, reduced lung injury score, lavage lactate dehydrogenase activity and neutrophil percentage.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…